Find your next paid study

National Institute on Drug Abuse (NIDA)NCT07637669

~$10 – $675

Actual pay is set by the research site.

Peripheral Artery Disease (PAD)

A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants With Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)

This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD),…

Regeneron PharmaceuticalsNCT07318610

~$50 – $2,100

Actual pay is set by the research site.

Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSmall Lymphocytic Lymphoma

Phase 2 Study of Time-Limited BGB-16673 and Sonrotoclax With MRD-Guided Addition of Obinutuzumab for Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This phase II trial tests how well tacabrutideg and sonrotoclax, with response-guided addition of obinutuzumab, works in treating patients with chronic lymphoc…

Fred Hutchinson Cancer CenterNCT07887061

~$75 – $2,000

Actual pay is set by the research site.

Premature Ovarian Insufficiency

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

Background: Premature ovarian insufficiency (POI) is a condition in which women under the age of 40 years have absent or irregular menstrual cycles. POI can c…

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT06851754

~$50 – $1,350

Actual pay is set by the research site.

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiat…

National Cancer Institute (NCI)NCT05675410

~$50 – $1,350

Actual pay is set by the research site.

Ganglioneuroblastoma, NodularNeuroblastoma

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, …

National Cancer Institute (NCI)NCT06172296

~$50 – $1,350

Actual pay is set by the research site.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)

Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isola…

Dystonia

Vima TherapeuticsNCT07304089

~$75 – $2,800

Actual pay is set by the research site.

Phase 1

An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line …

B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Nurix Therapeutics, Inc.NCT07520006

~$150 – $4,200

Actual pay is set by the research site.

Acute Respiratory Distress SyndromeInfections

A Phase 2 Randomized Double-blind Placebo-controlled Study To Evaluate The Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard Care For Moderate-to-Severe ARDS Due To Pneumonia Or Other Infections

BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN pl…

BioAegis Therapeutics Inc.NCT05947955

~$75 – $2,800

Actual pay is set by the research site.

Phase 1

A Phase Ib/II Study of Pembrolizumab, Ibrutinib and Rituximab in Refractory/Relapsed Primary Central Nervous System Lymphoma (PCNSL)

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The t…

Primary Central Nervous System LymphomaRecurrent CancerRefractory Cancer+1 more

Dana-Farber Cancer InstituteNCT04421560

~$150 – $4,500

Actual pay is set by the research site.

Progressive Supranuclear Palsy(PSP)

The Progressive Supranuclear Palsy Clinical Trial Platform

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investig…

~$75 – $3,000

Actual pay is set by the research site.

Adam BoxerNCT07173803

Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of …